Volume 4.38 | Oct 4

Prostate Cell News 4.38 October 4, 2013
Prostate Cell News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Prostate Cell News on Twitter
 
TOP STORY
Prostate Cancer Progression Correlates with Increased Humoral Immune Response to a Human Endogenous Retrovirus GAG Protein
Scientists studied the expression and immunogenicity of a human endogenous retrovirus (HERV)-K GAG protein encoded on chromosome 22q11.23 in relation to the clinical course of prostate cancer. In vitro expression of GAG-HERV-K was analyzed in panels of normal and malignant tissues, microarrays, and cell lines, and effects of demethylation and androgen stimulation were evaluated. [Clin Cancer Res] Abstract
Detect 7 times more prostate epithelial progenitors with ProstaCult
 
PUBLICATIONS (Ranked by impact factor of the journal)
LABORATORY RESEARCH

Estrogen Receptor β Upregulates FOXO3a and Causes Induction of Apoptosis through PUMA in Prostate Cancer
In human prostate cancer cells, researchers found that estrogen receptor β causes apoptosis by increasing the expression of pro-apoptotic factor p53-upregulated modulator of apoptosis (PUMA), independent of p53, but dependent on the forkhead transcription factor class-O family member, FOXO3a. [Oncogene] Abstract

Increased Expression of CYP24A1 Correlates with Advanced Stages of Prostate Cancer and Can Cause Resistance to Vitamin D3-Based Therapies
Scientists dissected the basis for the resistance to the vitamin D3 antitumor properties and specifically examined the effect of its major catabolic enzyme, CYP24A1, in prostate cancer. The use of CYP24A1 RNAi enhanced the cytostatic effects of vitamin D3 in human prostate cancer cells. [FASEB J] Abstract

Activation of the Wnt Pathway through Use of AR79, a Glycogen Synthase Kinase 3beta Inhibitor, Promotes Prostate Cancer Growth in Soft Tissue and Bone
Researchers determined if AR79 impacted progression of prostate cancer (PCa). AR79 inhibited beta-catenin phosphorylation, increased nuclear β-catenin accumulation in PCa and osteoblast cell lines and increased proliferation of PCa cells in vitro through beta-catenin. [Mol Cancer Res] Abstract

NSC126188 Induces Apoptosis of Prostate Cancer PC-3 Cells through Inhibition of Akt Membrane Translocation, FoxO3a Activation, and RhoB Transcription
Investigators showed that NSC126188 induces apoptosis of prostate cancer PC-3 cells by inhibiting Akt/FoxO3 signaling, which mediates RhoB upregulation. [Apoptosis] Abstract

Sodium Butyrate Induces Growth Inhibition and Apoptosis in Human Prostate Cancer DU145 Cells by Up-Regulation of the Expression of Annexin A1
Scientists investigated the mechanism of sodium butyrate action in prostate cancer DU145 cells. NaB significantly inhibited the growth and induction apoptosis of DU145 and PC3 cells in a dose-dependent manner. [PLoS One] Full Article

Withaferin A, a Steroidal Lactone from Withania somnifera, Induces Mitotic Catastrophe and Growth Arrest in Prostate Cancer Cells
Researchers focused on the cell cycle regulatory potential of the withanolide withaferin A (1) on prostate cancer cells. Compound 1 induced G2/M arrest in both prostate cancer cell lines when treated for 48 hours. [J Nat Prod] Abstract

Apoptotic Markers in a Prostate Cancer Cell Line: Effect of Ellagic Acid
Researchers delineated possible apoptotic pathway(s) involved in the ellagic acid (EA)-mediated chemotherapeutic effects in the LNCaP human prostatic cancer cell line. EA produced anti-proliferative effects through inhibition of rapamycin activation and a reduction in intracellular levels of β-catenin. [Oncol Rep] Abstract

Anti-Androgenic Activity of Hydroxyxanthones in Prostate Cancer LNCaP Cells
Investigators report that hydroxyxanthones from a plant extract act as anti-androgens in androgen receptor-positive prostate cancer LNCaP cells. [Fitoterapia] Abstract

Nuclear Targeting of Dystroglycan Promotes the Expression of Androgen Regulated Transcription Factors in Prostate Cancer
Researchers report an analysis of β-dystroglycan in prostate cancer in human tissue samples and in LNCaP cells in vitro. There is progressive loss of β-dystroglycan immunoreactivity from basal and lateral surfaces of prostate epithelia which correlates significantly with increasing Gleason grade. [Sci Rep] Full Article

CLINICAL RESEARCH

Exploratory Analysis of the Visceral Disease Subgroup in a Phase III Study of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer
An exploratory analysis of COU-AA-301 assessed whether abiraterone acetate (AA) improved overall survival (OS) in mCRPC patients with visceral disease progressing post docetaxel. AA plus prednisone produced similar absolute improvement in median OS in patients with and without visceral disease versus prednisone. [Prostate Cancer P D] Full Article

Listen Now: New Podcast on ALDH in Breast Cancer Treatment Response
 
REVIEWS
Molecular Imaging of Prostate Cancer with PET
The authors provide a concise review of the current state of affairs and potential future developments in the diagnostic utility of PET in prostate cancer. [J Nucl Med] Abstract

Visit our REVIEWS page to see a complete list of reviews in the prostate cell research field.
 
SCIENCE NEWS
New Study Shows Circulating Tumor Cell Enumeration – As Part of Composite Biomarker Panel – May Serve as a Surrogate for Efficacy Response in Metastatic Castration-Resistant Prostate Cancer
Janssen Diagnostics, LLC announced results from a study that demonstrated circulating tumor cell enumeration using CELLSEARCH®, along with lactate dehydrogenase as part of a composite biomarker panel, was an efficacy-response surrogate for survival in managing patients with metastatic castration-resistant prostate cancer. [Press release from PR Newswire LLC discussing research presented at the European Cancer Congress, Amsterdam] Press Release

From our sponsor: Learn about assays for cord blood. Download the free technical bulletin.
 
INDUSTRY NEWS
NxThera Announces First Patients Treated in Rezūm II IDE BPH Clinical Trial
NxThera, Inc. announced that Steven Gange, MD, of Western Urological Clinic and Jean Brown Research in Salt Lake City, Utah, used NxThera’s Rezūm® System to enroll and treat the first patients in NxThera’s Rezūm II U.S. investigational device exemption (IDE) clinical trial for the treatment of benign prostatic hyperplasia (BPH). [NxThera, Inc.] Press Release

National Cancer Institute Awards $48.6 Million Grant to MD Anderson
Broad, deep and outstanding research in cancer science, treatment and prevention have earned The University of Texas MD Anderson Cancer Center a $48.6-million, five-year grant from the National Cancer Institute and an “exceptional” ranking, the highest possible, from the National Cancer Institute’s extensive peer-review process. [The University of Texas MD Anderson Cancer Center] Press Release
 
POLICY NEWS
US Government Shuts Down
The US government entered a state of suspended animation on 1 October after Congress failed to agree on a budget for the next fiscal year, causing federal agencies – including those overseeing science policy and research – to shut down indefinitely. Most government scientists were ordered to stay at home, their offices and labs closed or run by a skeleton staff of ‘essential’ workers. The National Institutes of Health and the National Science Foundation stopped processing grants, some government websites were made inaccessible and many important research programmes were left hanging, potentially putting lives at risk in the case of some disease studies. [Nature News] Editorial

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW 2nd Anticancer Agents Congress: Targeting Cancer Stem Cell
November 21-24, 2013
Antalya, Turkey

Visit our events page to see a complete list of events in the prostate cell community.
 
JOB OPPORTUNITIES
NEW Postdoctoral Fellow – Mechanisms of DNA Damage in the Development and Progression of Prostate Cancer (Johns Hopkins Hospital)

NEW Senior Postdoctoral Researcher – Signaling and Metabolic Alterations in Prostate and Breast Cancer (CIC bioGUNE)

Research Technician Position – Steroid Receptor Signaling (Baylor College of Medicine)

Postdoctoral Research Associates – Tumor Immune Evasion Mechanism and Inflammation (Hollings Cancer Center)

Postdoctoral Fellow – Prostate Cancer and Head & Neck Cancer (University of Maryland Baltimore)

Research Associate – Prostate Cancer (University of Virginia)

Postdoctoral Position – Prostate Cancer Biology (University Of Rochester School Of Medicine)

Postdoctoral Position – Cancer Genomics and Epigenomics (Ontario Cancer Institute / Princess Margaret Hospital)

Scientist – Particle Chemistry (STEMCELL Technologies Inc.)

Research Technologist – Human Pluripotent Stem Cell Products (STEMCELL Technologies Inc.)

Research Technologist – Mesenchymal Cell Research (STEMCELL Technologies Inc.)

Research Technologist – Cell Culture Media & Matrices (STEMCELL Technologies Inc.)

Research Associate/Scientist – Antibodies Group (STEMCELL Technologies Inc.)

Research Associate – Particle Chemistry (STEMCELL Technologies Inc.)

Quality Control Analyst – Media (STEMCELL Technologies Inc.)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.
Learn more about Prostate Cell News: Archives | Events | Contact Us